Assessing the Possibility of Recurrent Diabetic Foot Ulcer Prevention via Remote Patient Monitoring: A Feasibility Study

Aims: Our main aims in this study of diabetic patients at risk of foot ulcers were to evaluate: (a) adherence to the use of an at-home thermal and visual digital foot scanner, (b) the feasibility of utilising thermovisual scan data to perform remote foot assessments, thereby enabling, if indicated, remote intervention by podiatrists and (c) the validity of scanned images to identify skin lesions consistent with those found at a podiatric clinical evaluation. Methods: In this single arm, open-label, 12-week pilot study in two countries, recruited patients with previous diabetic foot ulcer (DFU) (n = 27) were asked to stand on a digital foot scanner (OneStep), once a day at home. Plantar thermal and visual scan data were transmitted daily to a centralised monitoring service for daily review. Any abnormalities were immediately reported to the patient's podiatric healthcare provider, who determined appropriate intervention. Primary endpoints were patient adherence, device utility and data validity. Results: All participants with an active device (n = 26) took thermal and visual scans on 1547 days during 1940 active study days, averaging 5.3 ± 1.4 scans/week, with 80 ± 19% adherence (days scan recorded/days in study*100). Visual scans correctly identified all incident DFUs (n = 7). Podiatrists agreed that scans enabled the identification of skin integrity issues earlier than standard care (in 82% cases), finding visual scan images useful in 90% of reports and thermal data in 12%. Remote visual assessments agreed well with gold-standard podiatric examinations in identifying skin integrity risks (kappa = 0.67 [95% CI, 0.53–0.82, p < 0.001]), also showing good sensitivity (80%) and specificity (100%). Conclusions: Remote foot scanning was easy to perform and was used consistently by vulnerable patients. Scans were useful for remote podiatric foot assessments and interventions, and visual images identified DFUs/skin problems to a good level. We now aim to test this monitoring system in a larger scale randomised controlled trial for DFU prevention.